Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chitosan derivative with cross-linking polymerization and containing drug ligand

A chitosan derivative, cross-linking polymerization technology, applied in pharmaceutical science, instruments, glasses/goggles, etc., can solve the lack of drug interaction ligands, chitosan cannot be cross-linked, and it is difficult to achieve drug control Release and other issues, to achieve the effects of great social and economic benefits, good transparency, and good processability

Active Publication Date: 2013-01-09
JINLING INST OF TECH
View PDF5 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These carriers require a certain degree of cross-linking to be stable, but chitosan itself cannot be cross-linked, and small molecule cross-linking agents are often added, and these small molecule cross-linking agents usually have greater toxicity, which greatly limits its use. application
In addition, chitosan is a hydrophilic polysaccharide that lacks ligands that interact with drugs, making it difficult to achieve controlled release of drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chitosan derivative with cross-linking polymerization and containing drug ligand
  • Chitosan derivative with cross-linking polymerization and containing drug ligand
  • Chitosan derivative with cross-linking polymerization and containing drug ligand

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Add 3.0g of β-CD, 10.0mL of dimethyl sulfoxide (DMSO), and 10.0mL of isopropanol to the reactor in sequence, add 0.21mL of epichlorohydrin dropwise under magnetic stirring, and immediately add dropwise 0.55mol / L NaOH9 .15mL solution, after stirring for 4.5h, add 1% (m / m) CS / H 2 O50mL, continue to stir for 4.5h, dialyze for 72h, and freeze-dry to obtain the grafted product CC1; add it to the reactor, dissolve it in 100ml deionized water, and stir until completely dissolved. Add triethylamine 2.2mL, MAA 2.2mL and tetrabutylammonium bromide 2.2g to the previous CC1 / H 2 O solution, stirred at a constant temperature of 60 °C for 1 h. After the reaction, the solution was cooled to room temperature, dialyzed for about 72h, and freeze-dried to obtain the grafted product CCM1 (the Fourier transform infrared spectrogram of the relevant grafted product of this example is shown in the appendix figure 1 and NMR spectra are attached figure 2 ).

Embodiment 2

[0043] Add 1.5g of β-CD, 10.0mL of dimethyl sulfoxide (DMSO), 10.0mL of isopropanol to the reactor in sequence, add 0.21mL of epichlorohydrin dropwise under magnetic stirring, and immediately add dropwise 0.55mol / L NaOH9 .15mL solution, after stirring for 4.5h, add 1% (m / m) CS / H 2 O50mL, continued to stir for 4.5h, dialyzed for 72h, and freeze-dried to obtain the grafted product CC2; it was added to the reactor, dissolved in 100ml of deionized water, and stirred until completely dissolved. Add 2.2 mL of triethylamine, 2.2 mL of MAA and 2.2 g of tetrabutylammonium bromide to the previous CC2 / H 2 O solution, stirred at a constant temperature of 60 °C for 1 h. After the reaction, the solution was cooled to room temperature, dialyzed for about 72 hours, and freeze-dried to obtain the grafted product CCM2. Its infrared spectrum data: CC2, 1590cm -1 The primary amine peak is obviously weaker than 1650cm -1 Amide peak, 1450cm -1 The absorption peak of secondary amine (-NH-R) is ...

Embodiment 3

[0045] Add 6.0g of β-CD, 10.0mL of dimethyl sulfoxide (DMSO), and 10.0mL of isopropanol to the reactor in sequence, add 0.21mL of epichlorohydrin dropwise under magnetic stirring, and immediately add dropwise 0.55mol / L NaOH9 .15mL solution, after stirring for 4.5h, add 1% (m / m) CS / H 2 O50mL, continue to stir for 4.5h, dialyze for 72h, and freeze-dry to obtain the grafted product CC3; add it to the reactor, dissolve it in 100ml deionized water, and stir until completely dissolved. Add 2.2mL of triethylamine, 2.2mL of MAA and 2.2g of tetrabutylammonium bromide to the previous CC3 / H 2 O solution, stirred at a constant temperature of 60 °C for 1 h. After the reaction, the solution was cooled to room temperature, dialyzed for about 72 hours, and freeze-dried to obtain the grafted product CCM3. Its infrared spectrum data: CC3, 1590cm -1 The primary amine peak is obviously weaker than 1650cm -1 Amide peak, 1450cm -1 The absorption peak of secondary amine (-NH-R) is attributed to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a chitosan derivative with cross-linking polymerization and containing drug ligand. The chitosan derivative is a grafted substance formed by grafting a methacrylic acid substance and beta-cyclodextrin on a chitosan main chain, wherein the beta-cyclodextrin is grafted on the chitosan main chain through epoxy chloropropane; and the methacrylic acid substance is hydroxyethyl methylacrylate or methacrylic anhydride. The chitosan derivative provided by the invention has the beneficial effects that the processibility is good, and the controlled release of hydrophobic drugs can be realized; a hydrogel corneal contact lens prepared by the chitosan derivative has the advantages that the transparency is good, the water content, the water-retaining property and protein absorption capability are balanced, and the loading capability and the controlled release capability to the drugs are better than those of the existing material obviously. The chitosan derivative disclosed by the invention has the advantages that the synthetic route is simple, the operability is strong and the social and economic benefits are larger.

Description

technical field [0001] The invention belongs to the technical field of new materials, and in particular relates to a chitosan derivative capable of cross-linking polymerization and containing drug ligands and a preparation method thereof. Background technique [0002] At present, the treatment of many diseases is mainly completed by drugs. In drug therapy, a drug concentration that is too low cannot play a therapeutic role; a drug concentration that is too high will cause side effects and even damage normal tissues and organs. The treatment of eye diseases is a slow process, and the efficacy of drugs depends on whether a reasonable drug concentration can be maintained in the diseased part for a sufficient time. In the common pharmaceutical preparations currently used, when the drugs are absorbed into the human body, only a small part of the drugs can be effectively utilized, and most of the drugs are scattered throughout the body, resulting in low utilization rates and inef...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C08B37/08C08B37/16A61L31/04A61L31/16G02C7/04
Inventor 胡小红邱杰张国俊
Owner JINLING INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com